• Policy
• MET mutant anticancer drug Tepmetko challenges
• by Lee, Tak-Sun Aug 25, 2022 05:52am

• Policy
• Entry of HER2-low breast cancer Tx imminent in Korea
• by Lee, Hye-Kyung Aug 25, 2022 05:52am

• Policy
• 3rd gen ALK NSCLC drug Lorviqua to be listed on next month
• by Lee, Tak-Sun Aug 25, 2022 05:52am

• Policy
• Benefit for Sigmart 48mg will be newly established on Sept.
• by Kim, Jung-Ju Aug 25, 2022 05:52am

• Policy
• All domestic restrictions on PVA cut are agreed
• by Lee, Tak-Sun Aug 24, 2022 05:56am

• Policy
• Gov't “will reinvestigate overused reimbursed items”
• by Lee, Jeong-Hwan Aug 24, 2022 05:55am

• Policy
• Na Kyung-won is considering being the Minister of Health
• by Lee, Jeong-Hwan Aug 23, 2022 06:04am

• Policy
• Bill for 'state compensation for Paxlovid's side effects'
• by Lee, Jeong-Hwan Aug 23, 2022 06:04am

• Policy
• When will the CSO reporting system be legislated?
• by Lee, Jeong-Hwan Aug 23, 2022 06:04am

• Policy
• There is no concern about the disposal of COVID-19 PO tx
• by Lee, Jeong-Hwan Aug 23, 2022 06:03am